PureTech Health Plc (PRTC)
17.42
0.00 (0.00%)
Upcoming Events
Latest Headlines
PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
August 25, 2026 7:05 AM - BizWire
Celea Therapeutics to present Phase 3 IPF trial data at ERS Congress
August 25, 2026 7:00 AM - StreetInsider
Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (
August 25, 2026 7:00 AM - BizWire
Celea Therapeutics begins Phase 3 trial of deupirfenidone for IPF
July 13, 2026 2:01 AM - StreetInsider
Celea Therapeutics doses first patient in phase 3 IPF drug trial
July 13, 2026 2:00 AM - StreetInsider
PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
July 13, 2026 2:00 AM - BizWire
Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
July 13, 2026 2:00 AM - BizWire
Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
July 2, 2026 2:01 AM - BizWire
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
July 2, 2026 2:01 AM - BizWire
PureTech Health: Results of Annual General Meeting
June 10, 2026 1:14 PM - BizWire
Seaport Therapeutics reports positive phase 1 data for GlyphAgo anxiety drug
June 9, 2026 2:00 AM - StreetInsider
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
June 9, 2026 2:00 AM - BizWire
Full Article List
